CL
Climb Bio, Inc.
CLYM · NASDAQ
$14.05 -0.71% (-$0.10)
1M -17.45%
Market Cap $805.1M
P/E Ratio -
Div. Yield -
ROE 31.79%
Bulios Fair Price
$7.2
48.8% downside
Current Price
$14.05
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CLYM is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
61 /100
Fair P/B 3.36x
EV/EBITDA N/A
P/S N/A
Growth
66 /100
Stable Book val. growth 7.63%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 31.79%
ROA 23.40%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 31.45x
Debt/Equity 0.01x
Net debt/EBITDA N/A
Stability
29 /100
Unstable EPS volatility 30.88%
Profitable years 0
Beta 0.08x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CLYM
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Aoife Brennan BCh MMSc
Employees
28
Headquarters
Wellesley Hills
Upcoming events
11 NOV
Earnings
Upcoming earnings report